Temoporfin


Concise Prescribing Info
Indications/Uses
Palliation of advanced head and neck squamous cell carcinoma.
Dosage/Direction for Use
Adult : IV 150 mcg/kg via slow inj, followed by laser 96 hr later. Repeat 4 wk later if needed.
Dosage Details
Intravenous
Palliative treatment of advanced head and neck squamous cell carcinoma
Adult: 150 mcg/kg by slow IV Inj over at least 6 min. This is followed by laser (with 652 nm wavelength) for 200 seconds , sufficient to supply a dose of 20 J/cm2), 96 hr after inj. Repeat after 4 wk if necessary.
Incompatibility
Do not mix with other medicinal products or dilute with aqueous solutions
Contraindications
Porphyrias or other diseases exacerbated by light; tumours known to be eroding into a major blood vessel in or adjacent to the illumination site; planned surgical procedure within the next 30 days; coexisting ophth disease likely to require slit-lamp exam within the next 30 days; existing photosensitising therapy. Pregnancy, lactation.
Special Precautions
Avoid exposure to direct sunlight or bright indoor light for at least 15 days after admin, after which re-introduce to normal light gradually (sunscreen do not ofter any protection). Special care must be taken to prevent extravasation at the Inj site. If extravasation occurs, protect the area from light for at least 3 mth.
Adverse Reactions
Local haemorrhage, facial pain, facial oedema, burning sensation, inj site reaction, pain at inj site, scarring, mouth necrosis, dysphagia, nausea, vomiting, constipation, anaemia, giddiness, blisters, trismus, localised infection, fever, photosensitivity reaction, skin necrosis.
Drug Interactions
Increased skin photosensitivity when given with other photosensitisers such as topical fluorouracil.
Action
Description: Temoporfin is a porphyrin derivative, used as a photosensitiser in photodynamic therapy. The antitumour activity of temoporfin is activated with a light of 652 nm from a laser. The therapeutic effect is mediated through the generation of reactive O2 species, a process dependent on the intracellular interaction of temoporfin with light and oxygen.
Pharmacokinetics:
Distribution: Peak plasma concentrations: 2-4 hr (after IV infusion). Terminal plasma half-life: 65 hrs. Plasma protein binding: 85%.
Metabolism: Metabolised in the liver
Excretion: Excreted in the faeces via the bile.
Storage
Store below 25°C. Protect from light.
Disclaimer: This information is independently developed by MIMS based on Temoporfin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in